Drug Trial Radar · NCT04266301
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
530
Actual
Start
Jun 8, 2020
Primary completion
Oct 2, 2024
Study completion Oct 2, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult participants with intermediate, high or very high-risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator. The purpose of the current study was to assess clinical effects of MBG453 in combination with azacytidine in adult participants with IPSS-R intermediate, high, very high risk MDS and CMML-2.
Conditions
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
Interventions
SabatolimabDrug
A dose of MBG453 800 mg was administered intravenously (IV) every 4 weeks (Q4W).
AzacitidineDrug
A dose of Azacitidine 75 mg/m2 was administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
PlaceboDrug
A dose of placebo 800 mg was administered intravenously every 4 weeks (Q4W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) (Primary Efficacy Results)Time frame: up to approx. 39 months
- Overall Survival (OS) (Final Efficacy Results)Time frame: up to approx. 52 months
Locations
149 sites in 36 countries. Site status is shown where the registry gives one.
Yuma Regional Cancer Center
Yuma, Arizona
University of California LA
Los Angeles, California
Yale University School Of Medicine
New Haven, Connecticut
Mayo Clinic Jacksonville
Jacksonville, Florida
University Of Miami
Miami, Florida
Northwestern University
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Hackensack University Medical Ctr
Hackensack, New Jersey
Weill Cornell Medicine NY-Presb
New York, New York
University of Rochester Medical Ctr
Rochester, New York
University of Virginia
Charlottesville, Virginia
Novartis Investigative Site
Pilar, Buenos Aires, Argentina
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Perth, Western Australia, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Brasschaat, Belgium
Novartis Investigative Site
Roeselare, West-Vlaanderen, Belgium
Novartis Investigative Site
Florianópolis, Santa Catarina, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Viña del Mar, Valparaiso, Chile
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Jinan, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shenzhen, Guangdong, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Suzhou, Jiangsu, China
Novartis Investigative Site
Changchun, Jilin, China
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.